Alzheimer's Disease (AD) Clinical Trial
— PINK-ADOfficial title:
Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study
NCT number | NCT04570761 |
Other study ID # | DR200077 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | March 11, 2021 |
Est. completion date | March 2024 |
Alzheimer's disease (AD) is a neurodegenerative disorder affecting almost 6% of the world's population over the age of 65. This disease, in its most typical sporadic form, is characterized by an episodic memory impairment linked to a deficit in consolidation. Many studies indicate that sleep promotes this consolidation stage during the deep slow sleep stage by facilitating the transfer of information between the hippocampus and the neocortex. A method of acoustic brain stimulation at night by pink noises has been recently developed and has shown its effectiveness in strengthening memory consolidation in healthy volunteers. Actually, there is no study observing the effect of this new stimulation method on populations with neurodegenerative pathologies, in particular in AD for which this technique could potentially become a therapeutic option. The hypothesis is that of a strengthening of the memory consolidation capacities in subjects with AD as has been shown in healthy subjects.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | March 2024 |
Est. primary completion date | March 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria common to all participants: - Age> 50 years at the inclusion - Patient with regular sleep patterns - Patient having given written consent - Patient affiliated to a social security regimen Inclusion criteria for subjects with Alzheimer's disease: - Patient with a beginning Alzheimer's disease defined according to the criteria of the National Institute on Aging-Alzheimer's Association or carriers of a prodromal Alzheimer's disease defined according to the criteria of the International Working Group IWG-2; the diagnosis must be supported by brain imaging and a blood test carried out in routine care - MMSE score = 24 Inclusion criteria for healthy volunteers: - Absence of neurodegenerative pathologies - Matched in age (+/- 5 years) and in sex with a patient Non-inclusion criteria common to all participants: - Psychiatric pathologies (except depression or anxiety disorders stabilized for more than 3 months) - History of pathology which may have consequences on cognitive functioning and / or sleep: brain tumor, constituted stroke, epilepsy, head trauma (with clinical or parenchymal sequelae objectified on brain imagery), brain surgery - Any significant comorbidity likely to constitute a confounding factor according to the clinician - Psychotropic treatments introduced or modified <3 months before inclusion - Hypnotic and / or sedative treatments - Chronic consumption of alcohol or drugs - Legal incapacity and / or other circumstance rendering the patient unable to understand the nature, objective or consequences of the study - Major under guardianship or curatorship - Patient not French-speaking by birth or illiterate Exclusion Criteria common to all participants: - Sleep disorders defined by a score> 5 on the Pittsburg sleep quality index (PSQI) - A score> 10 on the Epworth sleepiness index |
Country | Name | City | State |
---|---|---|---|
France | University Hospital of Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. | gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. | Day 7 | |
Primary | difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. | gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. | Day 8 | |
Primary | difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. | gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. | Day 14 | |
Primary | difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. | gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the memory task of word matching. | Day 15 | |
Secondary | Number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. | gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. | Day 7 | |
Secondary | Number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. | gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. | Day 8 | |
Secondary | Number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. | gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. | Day 14 | |
Secondary | Number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. | gross variation of the difference between morning and eve of the number of reminders found between the "ON-stimulation" condition and the "OFF-stimulation" condition, on the ecological memory task. | Day 15 | |
Secondary | The memory complaint for Mc Nair's Questionnaire | score from 0 to 156.156 control of a bad score. The variation between J0 and J15 will be studied. | Baseline | |
Secondary | Psychoaffective aspects (Depression) for MADRS (Montgomery Asberg Depression Rating Scale) | score from 0 to 60.60 control of a bad score. The variation between J0 and J15 will be studied. | Baseline | |
Secondary | Psychoaffective aspects (Anxiety) for HAMA (Hamilton Anxiety) | score from 0 to 56.56 control of a bad score. The variation between J0 and J15 will be studied. | Baseline | |
Secondary | Quality of sleep for Pittsburgh Index (PSQI) | It is more an index of tolerance than efficiency. If the score is higher, the tolerance is lower. | Baseline | |
Secondary | The memory complaint for Mc Nair's Questionnaire | score from 0 to 156.156 control of a bad score. The variation between J0 and J15 will be studied. | Day 15 | |
Secondary | Psychoaffective aspects (Depression) for MADRS (Montgomery Asberg Depression Rating Scale) | score from 0 to 60.60 control of a bad score. The variation between J0 and J15 will be studied. | Day 15 | |
Secondary | Psychoaffective aspects (Anxiety) for HAMA (Hamilton Anxiety) | score from 0 to 56.56 control of a bad score. The variation between J0 and J15 will be studied. | Day 15 | |
Secondary | Quality of sleep for Pittsburgh Index (PSQI) | It is more an index of tolerance than efficiency. If the score is higher, the tolerance is lower. | Day 15 | |
Secondary | amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition | gross variation in the amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition, on an ambulatory EEG device | Day 7 | |
Secondary | amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition | gross variation in the amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition, on an ambulatory EEG device | Day 8 | |
Secondary | amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition | gross variation in the amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition, on an ambulatory EEG device | Day 14 | |
Secondary | amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition | gross variation in the amplitude of slow waves in deep slow sleep between the "ON-stimulation" condition and the "OFF-stimulation" condition, on an ambulatory EEG device | Day 15 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Recruiting |
NCT02854033 -
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
|
||
Completed |
NCT02681172 -
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
|
Phase 4 | |
Completed |
NCT02593318 -
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
|
Phase 1 | |
Completed |
NCT02264899 -
MEMENTO-VAScular COmponents of Dementia
|
N/A | |
Completed |
NCT02531360 -
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
|
Phase 0 | |
Not yet recruiting |
NCT05592678 -
δ in Dementia Clinical Trials
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05558709 -
Social-cognitive Functioning: Validation of a New Neuropsychological Test
|
N/A | |
Recruiting |
NCT05059158 -
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
|
||
Recruiting |
NCT02832921 -
Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk
|
N/A | |
Completed |
NCT02370524 -
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT01780519 -
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
|
Phase 1 | |
Completed |
NCT02103894 -
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
|
Phase 1 | |
Completed |
NCT03802162 -
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
|
Phase 1 | |
Completed |
NCT01231971 -
Alzheimer's Disease Neuroimaging Initiative 2
|
||
Recruiting |
NCT05291234 -
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
|
Phase 2 | |
Active, not recruiting |
NCT05771428 -
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
|
Phase 2 | |
Recruiting |
NCT06114745 -
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
|
Phase 1 |